BBP vs PBE

BBPAVirtus Biotech ETF

PBEBInvesco Biotechnology & Genome ETF

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

PBE Most biotech funds own the sector by size. PBE has run a different playbook since 2005: a quant screen on momentum, quality and value that narrows the field to roughly 30 names, reshuffled every quarter.

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

PBE The Fund seeks to track, before fees and expenses, the results of its designated biotechnology and genome benchmark index.

Why people hold it

• BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
• 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
• Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
• One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

• PBE The index scores biotech and genome companies on price momentum, earnings momentum, quality, management action and value, then reconstitutes quarterly, so the roster follows the scores.pionline.com
• Trading since 2005, one of the longest-running biotech ETFs on the tape, and it has stayed tight to the index it promises to follow.
• About 30 holdings, so an approval or a trial readout at one company registers in the portfolio instead of being diluted across a sprawling roster.
• Sits in the upper half of the biotech and genomics group on our review, with no structural red flags in the wrapper and a plain index mandate on file with the SEC.sec.gov

Worth knowing

• BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
• Income is not the point here. The fund has not been paying distributions, so the return story is price.
• An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

• PBE 0.59% sits above the category median, and above plain index rivals like IBB at 0.44% and XBI at 0.35%. The screening model is what you pay the difference for.
• Thinly traded next to the category's heavyweights, so spreads can be wider and bigger orders need more care at the point of execution.
• A 30-stock quant portfolio can diverge sharply from the broad biotech benchmark in either direction, and it pays out only quarterly.

Full BBP profile⁠

Full PBE profile⁠